Mechanism of Growth Inhibitory Effects of Cyclooxygenase-2 Inhibitor–NS398 on Cancer Cells

REFERENCES

• Simmons D. L., Levy D. B., Yannoni Y., Erikson R. L. Identification of a phorbol ester-repressible v-src-inducible gene. Proc Natl Acad Sci USA 1989; 86: 1178–1182
   PubMed Web of Science ®Google Scholar
• Jones D. A., Carlton D. P., McIntyre T. M., Zimmerman G. A., Prescott S. M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. Curr Opin Cell Biol 1993; 268: 9049–9054
   Google Scholar
• Subbaramaiah K., Telang N., Ramonetti J. T., Araki R., DeVito B., Weksler B. B., Dannenberg A. J. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996; 56: 4424–4429
   PubMed Web of Science ®Google Scholar
• Turini M. E., DuBois R. N. Cyclooxygenase-2: a therapeutic target. Annu Rev Med 2002; 53: 35–57
   PubMed Web of Science ®Google Scholar
• Beauchamp R. D., DuBois R. N. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996; 111: 1134–1140
   PubMed Web of Science ®Google Scholar
• Steinbach G., Lynch P. M., Phillips R. K., Wallace M. H., Hawk E., Gordon G. B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L. K., Levin B., Godio L., Patterson S., Rodriguez-Bigas M. A., Jester S. L., King K. L., Schumacher M., Abbruzzese J., DuBois R. N., Hittelman W. N., Zimmerman S., Sherman J. W., Kelloff G. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946–1952
   PubMed Web of Science ®Google Scholar
• Kargman S. L., O'Neill G. P., Vickers P. J., Evans J. F., Mancini J. A., Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995; 55: 3785–3789
   PubMedGoogle Scholar
• Eberhart C. E., Coffey R. J., Radhika A., Giardiello F. M., Ferrenbach S., DuBois R. N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183–1188
   PubMed Web of Science ®Google Scholar
• Molina M. A., Sitja-Arnau M., Lemoine M. G., Frazier M. L., Sinicrope F. A. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999; 59: 4356–4362
   PubMed Web of Science ®Google Scholar
• Ristimaki A., Honkanen N., Jankala H., Sipponen P., Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276–1280
   PubMed Web of Science ®Google Scholar
• Wu Q. M., Li S. B., Wang Q., Wang D. H., Li X. B., Liu C. Z. The expression of cox-2 in esophageal carcinoma and its realation to Clinicopathologic characteristic. Shijie Huaren Xiahua Zazhi 2001; 1: 12–14
   Google Scholar
• Zimmermann K. C., Sarbia M., Weber A. A., Borchard F., Gabbert H. E., Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59: 198–204
   PubMed Web of Science ®Google Scholar
• Leng J., Han C., Demetris A. J., Michalopoulos G. K., Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003; 38: 756–768
   PubMed Web of Science ®Google Scholar
• Wang X. H., Li S. B., Tong Q., Xie G. J., Wu Q. M. Effects of adenovirus-mediated human cyclooxygenase-2 antisense RNA on the growth of hepatocellular carcinoma. World J Gastroenterol 2005; 11(39)6110–6114
   PubMed Web of Science ®Google Scholar
• Thun M. J., Namboodiri M. M., Heath C. W. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593–1596
   PubMed Web of Science ®Google Scholar
• Schreinemachers D. M., Everson R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5: 138–146
   PubMed Web of Science ®Google Scholar
• Giovannucci E., Egan K. M., Hunter D. J., Stampfer M. J., Colditz G. A., Willett W. C., Speizer F. E. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609–614
   PubMed Web of Science ®Google Scholar
• Steinbach G., Lynch P. M., Phillips R. K., Wallace M. H., Hawk E., Gordon G. B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L. K., Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946–1952
   PubMed Web of Science ®Google Scholar
• van Stolk R., Stoner G., Hayton W. L., Chan K., DeYoung B., Kresty L., Kemmenoe B. H., Elson P., Rybicki L., Church J., Provencher K., McLain D., Hawk E., Fryer B., Kelloff G., Ganapathi R., Budd G. T., Phase I. trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res 2000; 6: 78–89
   PubMed Web of Science ®Google Scholar
• Labayle D., Fischer D., Vielh P., Drouhin F., Pariente A., Bories C., Duhamel O., Trousset M., Attali P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635–639
   PubMed Web of Science ®Google Scholar
• Sheng H., Shao J., Kirkland S. C., Isakson P., Coffey R. J., Morrow J., Beauchamp R. D., DuBois R. N. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99: 2254–2259
   PubMed Web of Science ®Google Scholar
• Zhang X., Morham S. G., Langenbach R., Young D. A. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 1997; 190: 451–459
   Web of Science ®Google Scholar
• Hanif R., Pittas A., Feng Y., Koutsos M. I., Qiao L., Staiano-Coico L., Shiff S. I., Rigas B. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin independent pathway. Biochem Pharmacol 1996; 52: 237–245
   PubMed Web of Science ®Google Scholar
• Mohan S., Epstein J. B. Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer. Oral Oncol 2003; 39: 537–546
   PubMed Web of Science ®Google Scholar
• Iniguez M. A., Rodriguez A., Volpert O. V., Fresno M., Redondo J. M. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol Med 2003; 9: 73–78
   PubMed Web of Science ®Google Scholar
• Richter M., Weiss M., Weinberger I., Furstenberger G., Marian B. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis 2001; 22: 17–25
   PubMed Web of Science ®Google Scholar
• Husain S. S., Szabo I. L., Tamawski A. S. NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am J Gastroenterol 2002; 97: 542–553
   PubMed Web of Science ®Google Scholar
• Kune G. A. Colorectal cancer chemoprevention: aspirin, other NSAID and COX-2 inhibitors. Aust N Z J Surg 2000; 70: 452–455
   PubMedGoogle Scholar
• Tsujii M., DuBois R. N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493–501
   PubMed Web of Science ®Google Scholar
• Hara A., Yoshimi N., Niwa M., Ino N., Mori H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn J Cancer Res 1997; 88: 600–604
   PubMedGoogle Scholar
• Sawaoka H., Kawano S., Tsuji S., Tsuji M., Gunawan E. S., Takei Y., Nagano K., Hori M. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998; 273: G1061–G1067
   Google Scholar
• Liu X. H., Yao S., Kirschenbaum A., Levine A. C. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998; 58: 4245–4249
   PubMed Web of Science ®Google Scholar
• Wang Xingpeng, Xu Xuanfu, Wang Bingxian, et al. Regulatory effect of cyclooxygenase-2 on the apoptosis of pancreatic adenocarcinoma cells and its possible mechanism. Zhong hua xiao hua za zhi 2002; 22(8)459–462
   Google Scholar